Last 48 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 25.21 | — | 35.58 | 49.35 | 228.57 | 19.02 | 4.88 | 22.73 | 39.04 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | +628.7% | +117.1% | +485.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 2.59 | 2.98 | — | 8.27 | 6.67 | 1.03 | 0.73 | 1.51 | 1.61 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +188.9% | — | +446.4% | +313.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | 12.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.1% | — | 100.0% | 59.8% | 100.0% | 47.7% | 100.0% | 100.0% | 100.0% | — | — | — | — | 100.0% | 38.2% | 35.3% | 33.7% | 39.8% | 39.6% | 41.0% | 40.7% |
| — | — | 0.0% | -40.2% | 0.0% | — | — | — | — | — | — | — | — | +151.0% | -3.7% | -13.9% | -17.2% | -5.7% | -2.7% | -2.8% | +2.4% | |
| Operating Margin | -1488.3% | — | -752.1% | -1010.1% | -3671.3% | -1655.0% | -870.3% | -1526.8% | -2152.5% | — | — | — | — | -3525.1% | -3.5% | -2.0% | -4.6% | -7.3% | -14.4% | -6.5% | -9.5% |
| — | — | +13.6% | +33.8% | -70.6% | — | — | — | — | — | — | — | — | -47985.4% | +75.5% | +68.9% | +51.7% | -480.4% | -834.2% | -1732.4% | +58.1% | |
| Net Margin | -2298.5% | — | -1884.8% | -1416.6% | -11575.9% | -1899.2% | -840.8% | -1449.1% | -2036.7% | — | — | — | — | -3341.7% | -5.7% | -10.3% | -6.0% | -10.3% | -18.8% | -13.4% | -16.6% |
| — | — | -124.2% | +2.2% | -468.4% | — | — | — | — | — | — | — | — | -32375.4% | +69.8% | +23.3% | +63.9% | -49.9% | -669.2% | -26.1% | +38.2% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -145.1% | -54.4% | -222.0% | -46.6% | -75.7% | -30.6% | -27.5% | -21.7% | -21.0% | — | — | -82.8% | — | -101.7% | -30.1% | -49.0% | -23.4% | -29.7% | -23.4% | -11.8% | -13.4% |
| — | -77.8% | -707.4% | -115.2% | -260.2% | — | — | +73.8% | — | — | — | -68.9% | — | -241.9% | -28.8% | -315.4% | -74.2% | -409.8% | -1046.6% | -31.4% | +38.2% | |
| ROA | -82.0% | -25.5% | -33.7% | -16.4% | -39.5% | -21.9% | -22.1% | -17.6% | -26.6% | -52.6% | -42.0% | -29.3% | -6.2% | -3.2% | -1.1% | -2.1% | -1.2% | -2.0% | -3.2% | -2.3% | -2.8% |
| — | -16.1% | -52.8% | +6.8% | -48.1% | +58.3% | +47.4% | +39.9% | -329.6% | -1554.1% | -3818.5% | -1294.3% | -398.0% | -58.1% | +66.3% | +9.0% | +55.3% | -55.6% | -596.7% | -16.0% | +45.7% | |
| ROIC | — | — | — | — | — | -2286.8% | -107.5% | -109.9% | — | — | — | -20.8% | -6.9% | -4.2% | -0.9% | -0.5% | -1.3% | -1.9% | -3.4% | -1.7% | -2.5% |
| — | — | — | — | — | — | — | -428.0% | — | — | — | -3708.1% | -445.3% | -127.2% | +74.2% | +67.0% | +49.9% | -394.8% | -639.1% | -1514.8% | +61.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.06 | — | 0.07 | 0.04 | 0.16 | 0.18 | 0.15 | 0.14 | — | — | 0.70 | — | 23.02 | 19.62 | 16.81 | 13.19 | 10.97 | 8.62 | 2.73 | 2.61 |
| — | -62.4% | — | -55.0% | -69.8% | — | — | -78.2% | — | — | — | -95.8% | — | +109.8% | +127.6% | +516.1% | +405.6% | +383.3% | +305.7% | +27.4% | +22.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 80.27 | — | 155.97 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.35 | 6.42 | 4.70 | 6.15 | 7.35 | 9.83 | 5.60 | 8.02 | 6.92 | 0.47 | 1.90 | 1.90 | 5.13 | 1.74 | 1.69 | 1.64 | 1.68 | 1.86 | 1.97 | 2.01 | 2.04 |
| — | -34.7% | -16.0% | -23.4% | +6.3% | +2013.2% | +194.9% | +322.4% | +34.9% | -73.2% | +12.3% | +15.7% | +204.5% | -6.8% | -14.0% | -18.2% | -17.5% | -9.6% | -7.0% | +0.4% | +1.8% | |
| Quick Ratio | 7.35 | 6.42 | 4.70 | 6.15 | 7.35 | 9.83 | 5.60 | 8.02 | 6.92 | 0.47 | 1.90 | 1.90 | 5.13 | 1.43 | 1.45 | 1.42 | 1.47 | 1.62 | 1.74 | 1.80 | 1.83 |
| — | -34.7% | -16.0% | -23.4% | +6.3% | +2013.2% | +194.9% | +322.4% | +34.9% | -67.4% | +31.3% | +34.1% | +247.6% | -12.0% | -16.9% | -21.4% | -19.3% | -14.3% | -9.7% | +1.5% | +7.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | -9.56 | -7.84 | -1.50 | -0.98 | -2.21 | -3.65 | -6.09 | -1.15 | -1.71 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CAMP stock.
CAMP4 Therapeutics Corporation's current P/E is -2.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CAMP4 Therapeutics Corporation's current operating margin is -1488.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CAMP4 Therapeutics Corporation's business trajectory between earnings reports.